Fig. 1 · Structure

Documents & Downloads

Pravastatin sodium

Cat. No. A11912 CAS 81131-70-6

HMG-CoA reductase inhibitor

Pravastatin sodium is a water-soluble, competitive inhibitor of 3-hydroxy-3-methyl coenzyme A (HMG-CoA) reductase. Potently blocks cholesterol synthesis in vivo (Ki~ 1 nM) and displays cardioprotective properties.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
HMG-CoA reductase 5.6 μM

Cellular Effect

Cell Line Activity Value Description Reference
HepG2 IC50 > 200 μM Antimalarial activity against Plasmodium berghei NK65 infected in human HepG2 cells after 48 hrs by RT-PCR [PMID: 20457823]

In Vitro Studies

Pravastatin produced no reduction in cell viability in A2780 ovarian cancer cells after incubation for 48 hrs. In SM9-1 trophoblast cells, Pravastatin increased VEGF release in a dose dependent manner after 24 hours. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Unchanged viability in ovarian cancer cells

Cell-based study · A2780 ovarian cancer cells [1]

A2780 ovarian cancer cells were incubated with Pravastatin at 0.1–1-10 uM for 48 hrs. No reduction in cell viability was observed by MTS assays.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viability was measured by MTS assays.Reported result 0.1–1-10 uM, 48 hrs: No reduction in cell viability was observed with pravastatin.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.1–1-10 uM
Exposure duration
48 hrs
Method
incubated
Vehicle
distillated water
Methods and source locations

Compound reported in the paper: Pravastatin

The paper names Pravastatin without stating the salt or form; not verified as the sodium form supplied as A11912. No dose conversion or lot validation.

Materials and methods > Reagents (S2); Results > Lipophilic (lovastatin and simvastatin) but not hydrophilic (pravastatin) statins mediate apoptosis in ovarian cancer cell lines (S64, S66); Fig 1 legend (S118, S119, S121)

Cell viability was measured by MTS assays.: Cell viability was measured by MTS assays.; comparator: vehicle (DMSO) — Results > Lipophilic (lovastatin and simvastatin) but not hydrophilic (pravastatin) statins mediate apoptosis in ovarian cancer cell lines (S64, S66); Fig 1 legend (S119)

Dose dependent VEGF release in trophoblast cells

Cell-based study · SM9-1 trophoblast cells [2]

SM9-1 trophoblast cells were incubated with Pravastatin at 5 µg/ml, 10 µg/ml and 20 µg/ml for 24 hours. VEGF release increased in a dose dependent manner, as measured in supernatants by ELISA.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
VEGF levels were measured in the supernatants by ELISAReported result 5, 10 and 20 µg/ml; After 24 hours: SM9-1 trophoblast cells incubated with pravastatin showed increase VEGF release in a dose dependent manner (*p<0.05).[2]

Literature-Reported Treatment Conditions

Treatment concentration
5 µg/ml, 10 µg/ml and 20 µg/ml
Exposure duration
24 hours
Method
incubated with different concentrations of pravastatin
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Pravastatin

The paper names Pravastatin without stating the salt or form; not verified as the sodium form supplied as A11912. No dose conversion or lot validation.

Materials and Methods > Trophoblast cells culture (S124, S125, S126); Figure 4 legend (S171, S172)

VEGF levels were measured in the supernatants by ELISA: VEGF levels were measured in the supernatants by ELISA; comparator: control values — Materials and Methods > Trophoblast cells culture (S125, S126); Figure 4 legend (S171)

In Vivo Studies

In pregnant CBA/J x DBA/2 mice, Pravastatin treatment was associated with a lower MAP response to Ang II injection compared with untreated mice. In C57BL/6J wild-type female mice receiving a normal diet, significantly different OTUs differentiated the vehicle and Pravastatin groups. [2,3]

Reduced Ang II response in pregnant mice

Animal study · CBA/J x DBA/2 mice [2]

Pregnant CBA/J x DBA/2 mice received Pravastatin at 20 ug/kg sc daily. The MAP response to Ang II injection was lower than in untreated CBA/J x DBA/2 mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MAP was measured before and 10 minutes after Ang II injectionMAP response to Ang II 12±3 mmHg[2]

Conditions shared by the study groups

Route
sc
Treatment course
daily from day 4 to 12 of pregnancy
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Pravastatin 20 ug/kguntreated CBA/J x DBA/2 mice20 ug/kg, sc, daily from day 4 to 12 of pregnancy: response to Ang II: 12±3 vs 32±5 mmHg, p<0.01.[2]
Pravastatin 20 ug/kg
Model: CBA/J x DBA/2 mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Pravastatin

The paper names Pravastatin without stating the salt or form; not verified as the sodium form supplied as A11912. No dose conversion or lot validation.

Results > Pravastatin prevents preeclamptic features in CBA/J x DBA/2 mice (S63); Materials and Methods > Mice matings and treatment protocol (S87); Materials and Methods > Blood Pressure Measurements (S107, S108)

MAP was measured before and 10 minutes after Ang II injection: MAP was measured before and 10 minutes after Ang II injection; comparator: untreated CBA/J x DBA/2 mice — Results > Pravastatin prevents preeclamptic features in CBA/J x DBA/2 mice (S63); Materials and Methods > Mice matings and treatment protocol (S87); Materials and Methods > Blood Pressure Measurements (S108)

Pravastatin 20 ug/kg · Results > Pravastatin prevents preeclamptic features in CBA/J x DBA/2 mice (S63); Materials and Methods > Mice matings and treatment protocol (S87)

Differentially abundant OTUs in mice receiving a normal diet

Animal study · C57BL/6J wild-type female mice [3]

C57BL/6J wild-type female mice on a normal diet received Pravastatin at 10 mg kg−1 daily by gastric gavage for 12 weeks. Significantly different OTUs differentiated the vehicle and Pravastatin groups.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
differentially abundant OTUsdifferentially abundant OTUs Six significantly different OTUs[3]

Conditions shared by the study groups

Route
gastric gavage
Treatment course
12 weeks; administered daily; at noon
Vehicle
sterile water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Pravastatin 10 mg kg−1control cohort (ND-vehicle)Normal diet (ND); 10 mg kg−1, administered daily via gastric gavage; 12 weeks: Six significantly different OTUs were obtained that differentiated between the vehicle and the pravastatin groups.[3]
Pravastatin 10 mg kg−1
Model: C57BL/6J wild-type female mice
Methods and source locations

Compound reported in the paper: Pravastatin

The paper names Pravastatin without stating the salt or form; not verified as the sodium form supplied as A11912. No dose conversion or lot validation.

Results > Altered host physiology in response to statins (S3); Results > Statin treatment alters gut microbiota (S23, S31); Results > Characterisation of the statin-associated gut microbiota (S35, S40); Methods > Mice treatment (S134, S135, S136)

differentially abundant OTUs: differentially abundant OTUs; comparator: control cohort (ND-vehicle) — Results > Altered host physiology in response to statins (S3); Results > Statin treatment alters gut microbiota (S31); Results > Characterisation of the statin-associated gut microbiota (S40); Methods > Mice treatment (S134, S136)

Pravastatin 10 mg kg−1 · Results > Altered host physiology in response to statins (S3); Results > Characterisation of the statin-associated gut microbiota (S40); Methods > Mice treatment (S134, S136)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 81131-70-6
Applications HMG-CoA reductase inhibitor
Formula C23H35NaO7
Molecular Weight 446.51
Synonyms Eptastatin sodium
SMILES
CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)[O-])O)O)O.[Na+]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 79 mg/mL (176.92 mM)
Water 79 mg/mL (176.92 mM)
Ethanol 11 mg/mL (24.63 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Kato S, Smalley S, Sadarangani A, et al. Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase. J Cell Mol Med (2010). PMID: 19432822 DOI: 10.1111/j.1582-4934.2009.00771.x Source material
  2. [2] Ahmed A, Singh J, Khan Y, et al. A new mouse model to explore therapies for preeclampsia. PLoS One (2010). PMID: 21048973 DOI: 10.1371/journal.pone.0013663 Source material
  3. [3] Caparrós-Martín JA, Lareu RR, Ramsay JP, et al. Statin therapy causes gut dysbiosis in mice through a PXR-dependent mechanism. Microbiome (2017). PMID: 28793934 DOI: 10.1186/s40168-017-0312-4 Source material

Added to your cart

View Cart Checkout
Loading...